CASI Pharmaceuticals: Strategic Divestments and Promising Clinical Developments Drive Buy Rating

CASI Pharmaceuticals (CASI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA from H.C. Wainwright maintained a Buy rating on the stock and has a $4.00 price target.

Sean Lee CFA has given his Buy rating due to a combination of factors including strategic divestments and promising clinical developments. CASI Pharmaceuticals has recently entered into an agreement to sell its China business to Kaixin Pharmaceuticals, which will allow the company to focus its resources on the development of CID-103. This monoclonal antibody has shown superior activity and reduced toxicity compared to existing treatments in preclinical and Phase 1 studies, and is currently being tested in a Phase 1/2 study for immune thrombocytopenia (ITP). The company plans to expand CID-103’s applications to other indications such as aplastic anemia and transplant-related antibody mediated rejection, which together represent a significant market opportunity.
Financially, CASI reported revenues of $6.2 million for the first quarter of 2025, slightly above consensus estimates, and has a cash position of $10.9 million, which is considered sufficient to fund its operations. The analyst maintains a 12-month price target of $4.00 per share, based on a combination of price-sales and price-earnings multiple analyses. Despite potential risks such as clinical, regulatory, and financial challenges, the strategic focus on CID-103 and the divestment of non-core assets underpin the Buy rating.

According to TipRanks, Lee CFA is an analyst with an average return of -3.3% and a 31.02% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Verastem, Cytosorbents, and Alphatec Holdings.